sarepta therapeutics nasdaq

News

Sarepta Therapeutics Stock Plunges

Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy

Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD).

· 2d

Gene Therapy Maker Sarepta Tells FDA It Won't Halt Shipments Despite Patient Deaths

· 3d

Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies

Sarepta Therapeutics Stock Is Surging After The Bell: What's Going On?

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares are soaring in Wednesday’s after-hours session after the company announced a ...

5don MSN

Sarepta Therapeutics rises after restructuring, pipeline focus

Sarepta Therapeutics (NASDAQ:SRPT) saw its stock rise in after-hours trading following the announcement of a strategic review ...

Sarepta Therapeutics: What's Happening With SRPT Stock?

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Nasdaq4y

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Just Reported And Analysts ...

Investors in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) had a good week, as its shares rose 3.3% to close at US$87.11 following the release of its yearly results. The statutory results were mixed ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results